B cells in antibody-mediated kidney transplant rejection: their characteristics and what they react to.
Official title: Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity
Run by Assistance Publique - Hôpitaux de Paris · NCT07134491 · Data updated 2026-11-12
This project will test whether B cells taken from kidney transplant patients with suspected antibody-mediated rejection produce antibodies that react to donor HLA, other targets, or gut microbes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 2 sites (Paris and 1 other locations) |
| Status | Recruiting |
| Started | March 13, 2026 |
| Main results expected | March 13, 2029 |
| Study ends | March 13, 2029 |
| Registry record updated | March 18, 2026 |
| Trial ID | NCT07134491 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult kidney transplant recipients admitted for biopsy or graft removal who can provide informed consent and are affiliated with a health insurance system are ideal candidates.
✕Probably not a fit
Patients with confounding renal infections (acute or recurrent pyelonephritis, BK virus nephropathy), pregnant or breastfeeding women, and those under legal protection are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adult kidney transplant recipients who undergo a biopsy for suspected rejection or surgical graft removal will be enrolled alongside control patients with non-inflammatory findings. Investigators will extract and culture B cells from blood and kidney tissue, collect stool and blood samples, and test the antibodies those B cells produce for reactivity to HLA, non-HLA targets, and components of the gut microbiome. High-throughput sequencing of immunoglobulin genes will be used to characterize B-cell repertoires in both peripheral blood and intrarenal compartments. The study is observational and aims to link B-cell phenotypes and antibody specificities with clinical rejection events.
Why it matters
Potential benefit: If successful, the results could identify triggers and specific antibody targets that help guide more precise prevention or treatment strategies to reduce graft loss.
How similar studies have gone: Previous work has characterized B-cell roles and anti-HLA antibodies in rejection, but combining paired intrarenal and peripheral B-cell profiling with microbiome reactivity and high-throughput immunoglobulin sequencing is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult kidney transplant recipients admitted for biopsy or graft removal in the participating nephrology departments. * Patient participation agreement and signed consent form * Affiliation to a health insurance system Exclusion Criteria: * Confounding factor of renal inflammation: acute or recurrent pyelonephritis, BK virus nephropathy * Pregnant or breast-feeding women * Persons under legal protection
Where it's running
-
Nephrology department, Hôpital Pitié Salpêtière
Paris, France Recruiting -
Nephrology department, Tenon hospital
Paris, France Not yet recruiting
Study contacts
- Study coordinator: Yanis TAMZALI, MD, MsC
- Email: yanis.tamzali@aphp.fr
- Phone: 681402564
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BiTE therapy for chronic active antibody-mediated rejection after kidney transplant
This study tests whether a BCMA×CD3 Bispecific T-cell Engager can help kidney transplant patients with chronic active antibody-mediated rejection.
-
Use of extracorporeal photopheresis in kidney transplant recipients with antibody-mediated rejection
This study looks at kidney transplant patients who had antibody-mediated rejection and were treated with extracorporeal photopheresis to see how they fare over a year.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.